Expert Answers to HCP Questions on CAR T-Cell Therapy
Listen to experts answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy for patients with hematologic malignancies.
Decera Clinical Education Oncology Podcast · Jae H Park MD, Noopur Raje MD, Caron A Jacobson MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including:
- At what time in the treatment journey should CAR T-cell therapy be considered?
- How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?
- How is CAR T-cell therapy best used for multiple myeloma?
- What qualities of bridging therapy are most preferred?
- When do patients receiving CAR T-cell therapy need COVID-19 or other vaccinations?
- How are steroids optimally used in managing CAR T-cell therapy–related toxicities?
Presenters:
Caron A. Jacobson, MD
Assistant Professor
Division of Medical Oncology
Department of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
Jae H. Park, MD
Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York
Noopur Raje, MD
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on an online CME program supported by an educational grant from Bristol-Myers Squibb.
Link to full program:
https://bit.ly/3BfbEOf
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.